Summary:
Masimo’s board of directors has appointed Katie Szyman as its new chief executive officer, effective Feb 12, following a search process. Alongside this transition, Michelle Brennan has been appointed chairman of the board, while Quentin Koffey has been named vice chairman. Szyman brings experience in patient monitoring, medical technology, and corporate leadership, having previously held executive roles at BD, Edwards Lifesciences, and Medtronic. Masimo’s leadership team expects these changes to support the company’s focus on innovation, revenue growth, and operational improvements.
Key Takeaways:
- Katie Szyman Appointed as Masimo’s CEO – Szyman was selected after a board-led search process and brings experience in patient monitoring and corporate leadership.
- Board Leadership Changes Announced – Michelle Brennan has been named chairman of the board, and Quentin Koffey will serve as vice chairman.
- Leadership Transition Aims to Strengthen Growth and Innovation – Szyman’s expertise in medical technology and financial leadership aligns with Masimo’s strategy to enhance innovation and operational performance, according to a release from Masimo.
Masimo’s board of directors announced that Katie Szyman has been appointed as the company’s next chief executive officer.
Interim chief executive officer Michelle Brennan has been appointed chairman of Masimo’s board, and lead independent director Quentin Koffey has been appointed vice chairman. These changes are effective as of Feb 12.
Szyman is currently worldwide president of advanced patient monitoring at BD (Becton, Dickinson, and Company). While at Edwards, Szyman accelerated revenue growth in the critical care product group through several initiatives, including entering adjacent markets through internal and external innovation and introducing the first artificial intelligence technology cleared by the Food and Drug Administration in the patient monitoring space.
Previously, Szyman led the critical care product group at Edwards Lifesciences, which was acquired by BD in a transaction that closed in September 2024. Szyman also spent more than 20 years at Medtronic, where she held positions with increasing levels of responsibility inside and outside the US, including leadership roles in corporate strategy, business development, and finance, and as the worldwide president of both the endovascular and diabetes business units.
Her appointment follows a search process overseen by the board with the assistance of executive recruitment firm Korn Ferry. During this process, the board evaluated numerous internal and external candidates. The board concluded that Szyman was the right choice given her successful track record of accelerating revenue growth by bringing new patient monitoring products to market, experience leading and retaining top industry talent, and deep existing relationships within the sector.
Guiding Masimo’s Next Phase of Growth
According to a release from Masimo, Szyman possesses operational and financial leadership experience that will aid Masimo as it continues to address its cost structure and improve gross margin performance. Szyman also brings public company board experience, including serving as a director of Inari Medical since 2019. Szyman previously served on the boards of Outset Medical, the Edwards Lifesciences Foundation, and the Opus School of Business at the University of St Thomas.
“Katie’s more than 35 years of relevant experience and her unique mix of expertise set her apart during our search and make her an ideal fit to lead the next innovation-focused stage of Masimo’s evolution,” says Koffey in a release. “We also want to thank Michelle for her exemplary performance in the interim CEO role, particularly in leading a seamless transition for customers, employees, and shareholders from day one. We look forward to continuing to benefit from her experience and judgment as she moves into her new position as chairman of the board.”
Szyman says in a release, “I have long admired Masimo as an innovation leader, and I could not be more excited about the opportunity to grow the business and deliver improved outcomes for millions more patients around the world. I believe Masimo’s leadership team and bench of talent is top tier, and I am thrilled by the chance to work with and learn from this group.”
Szyman received a BA from the University of St Thomas and an MBA from Harvard Business School.
ID 31111264 © Jakub Jirsak | Dreamstime.com
